Is Imatinib produced by Zhengda Tianqing?

Imatinib (Imatinib) is a domestic drug produced in China by Chia Tai Tianqing. Imatinib was launched in China as early as 2003. The domestic medical insurance price is about 700 yuan, and the specification is 100mg*60. Due to the large differences in medical insurance in different places, please consult the local pharmacy or medical insurance bureau for specific prices. Foreign medicines are divided into original drugs and generic drugs. Original drugs are mainly Turkish original drugs, and the price is relatively high, about 3300 yuan; generic drugs are mainly Indian generic drugs, and the Indian generic drugs specifications 100mg*120 are priced at around a few hundred yuan, which is much cheaper than domestic ones. The ingredients of foreign original drugs and generic drugs are basically the same as those of domestic imatinib.

The main mechanism of action of imatinib involves its key properties as a targeted therapy. It acts on cancer cells by inhibiting abnormal kinase activity. Specifically, the primary targets of imatinib include the BCR-ABLfusion protein, which is common in patients with chronic myeloid leukemia (CML), and the KITtyrosine kinase, which is common in patients with cortical renal cancer (GIST). It inhibits the growth and spread of cancer cells by precisely intervening in these abnormal tyrosine kinase activities.

Imatinib is mainly used to treat malignant tumors such as CML, acute lymphoblastic leukemia (ALL) and GIST. Imatinib has been used with remarkable success in patients with CML and GIST, transforming these cancers from potentially fatal diseases to manageable chronic conditions.

Imatinib generally causes fewer side effects than traditional chemotherapy drugs, making it easier for patients to tolerate treatment and thus improving quality of life. Patients can usually continue with their normal daily activities and work without too much concern about discomfort caused by treatment.